MA38782A1 - Dry powder formulation with anticholinergic, corticosteroid and beta-adrenergic for administration by inhalation - Google Patents
Dry powder formulation with anticholinergic, corticosteroid and beta-adrenergic for administration by inhalationInfo
- Publication number
- MA38782A1 MA38782A1 MA38782A MA38782A MA38782A1 MA 38782 A1 MA38782 A1 MA 38782A1 MA 38782 A MA38782 A MA 38782A MA 38782 A MA38782 A MA 38782A MA 38782 A1 MA38782 A1 MA 38782A1
- Authority
- MA
- Morocco
- Prior art keywords
- anticholinergic
- corticosteroid
- inhalation
- adrenergic
- beta
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne des formulations de poudre sèche pour l'inhalation, comprenant une combinaison d'un anticholinergique, d'un agoniste de l'adrénorécepteur de bêta2 à action prolongée et d'un corticostéroïde, leur procédé de préparation et des utilisations thérapeutiques de ces formulations.Inhalable powder formulations for inhalation comprising a combination of an anticholinergic, a long-acting beta2 adrenoreceptor agonist and a corticosteroid, a process for their preparation and therapeutic uses of these formulations.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13176114 | 2013-07-11 | ||
PCT/EP2014/064824 WO2015004243A1 (en) | 2013-07-11 | 2014-07-10 | Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation |
Publications (2)
Publication Number | Publication Date |
---|---|
MA38782A1 true MA38782A1 (en) | 2016-04-29 |
MA38782B1 MA38782B1 (en) | 2016-11-30 |
Family
ID=48793010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA38782A MA38782B1 (en) | 2013-07-11 | 2016-01-08 | Dry powder formulation with anticholinergic, corticosteroid and beta-adrenergic for administration by inhalation |
Country Status (2)
Country | Link |
---|---|
AR (1) | AR096878A1 (en) |
MA (1) | MA38782B1 (en) |
-
2014
- 2014-07-10 AR ARP140102562A patent/AR096878A1/en not_active Application Discontinuation
-
2016
- 2016-01-08 MA MA38782A patent/MA38782B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
AR096878A1 (en) | 2016-02-03 |
MA38782B1 (en) | 2016-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY176176A (en) | Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation | |
EA201892657A1 (en) | SPYROLACTAM MODULATORS OF THE NMDA-RECEPTOR AND THEIR APPLICATION | |
PH12015501595A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
EA033113B1 (en) | Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide | |
PH12015501598A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
MA35859B1 (en) | Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation | |
IN2014DN10548A (en) | ||
PH12015501600A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
PH12015501601B1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
MA43256B1 (en) | Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic | |
PH12015501596A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
MA39735A (en) | Dosing of cabozantinib formulations | |
MD20150120A2 (en) | Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose | |
UA117154C2 (en) | S1p3 antagonists | |
MX2017013636A (en) | Tamper-resistant fixed dose combination providing fast release of two drugs from different particles. | |
MX2019006942A (en) | Non-peptide oxytocin receptor agonists. | |
MX2017013633A (en) | Tamper-resistant fixed dose combination providing fast release of two drugs from particles. | |
MA38782B1 (en) | Dry powder formulation with anticholinergic, corticosteroid and beta-adrenergic for administration by inhalation | |
HRP20230105T1 (en) | N,n-bis-2-mercaptoethyl isophthalamide for the treatment of neurodegenerative diseases | |
TW201613600A (en) | Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically | |
BR112014029577A2 (en) | use of inverse ghrelin receptor agonists or antagonists for the treatment of sleep disorders | |
Breccia | Dasatinib/vincristine | |
Solla | Levodopa/pergolide | |
GR1008039B (en) | Stable injectable pharmaceutical composition of vitamin d receptor agonist and process for preparation thereof |